Anti-SARS-CoV-2 REGN-COV2

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Anti-SARS-CoV-2 REGN-COV2
DrugBank Accession Number
DB15691
Background

Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.1 Two upcoming publications in the journal, Science, will provide additional information about preclinical research with the Anti-SARS-COV-2 REGN-COV2 antibody cocktail.2

Clinical trials for this drug started on June 11, 2020. Regeneron's clinical trial will study the effects of this drug on hospitalized COVID-19 patients, symptomatic COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection, including contacts of an infected individual.1

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • REGN-COV2
  • REGN10933+REGN10987 combination therapy

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ASpike glycoprotein
binder
SARS-CoV-2
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 [Link]
  2. Regeneron: Regeneron begins first clinical trials of antibody-antiviral cocktail REGN-COV-2 for the treatment and prevention of COVID-19 [Link]
Wikipedia
REGN-COV2

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Healthy Volunteers1
2Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2Not Yet RecruitingTreatmentChronic Stable Illness / Coronavirus Disease 2019 (COVID‑19) / Healthy Volunteers1
2, 3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2, 3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Severe Acute Respiratory Syndrome1
1Active Not RecruitingTreatmentChronic Stable Illness / Coronavirus Disease 2019 (COVID‑19) / Healthy Volunteers1
1, 2Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
Not AvailableAvailableNot AvailableCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
SARS-CoV-2
Pharmacological action
Yes
Actions
Binder
General Function
Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses also human TMPRSS2 for priming in human lung cells which is an essential step for viral entry (PubMed:32142651). Can be alternatively processed by host furin (PubMed:32362314). Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.
Specific Function
Host cell surface receptor binding
Gene Name
S
Uniprot ID
P0DTC2
Uniprot Name
Spike glycoprotein
Molecular Weight
141177.29 Da
References
  1. Matthews DB: A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol. 2020 Oct;20(10):591. doi: 10.1038/s41577-020-00431-9. [Article]
  2. Regeneron: Regeneron begins first clinical trials of antibody-antiviral cocktail REGN-COV-2 for the treatment and prevention of COVID-19 [Link]

Drug created on June 15, 2020 15:31 / Updated on October 12, 2020 17:26